Proof-of Concept Study of Topical 3%-Diclofenac-Nano-Emulsion Cream for Knee OA Pain

NCT ID: NCT00484120

Last Updated: 2011-08-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 123 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2008-12-31

Brief Summary

This study valuates the safety and efficacy of treatment with 3% Diclofenac Nano-Emulsion Cream versus Placebo in subjects with osteoarthritis of the knee.

Detailed Description

This will be a multi-center, double-blind, placebo-controlled, multiple-dose, parallel treatment study. A total of 126 subjects will be randomized to receive either 3%-Diclofenac-NE cream or a placebo cream respectively. Following screening and a washout period from previous treatments subjects will be enrolled and will self-apply the study medication. During the study, subjects will apply 3%-Diclofenac-NE or placebo cream three times daily for 28 days and complete a home-diary. Subjects will visit the clinic at mid-treatment for a follow up examination and again for a final examination at the end of treatment.

Conditions

Osteoarthritis of the Knee

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

3% Diclofenac NE cream

Group Type: EXPERIMENTAL

3%-Diclofenac-Nano-Emulsion Cream

Intervention Type: DRUG

3%-Diclofenac-Nano-Emulsion Cream

2

Group Type: PLACEBO_COMPARATOR

Placebo cream

Intervention Type: DRUG

Placebo cream

Interventions

3%-Diclofenac-Nano-Emulsion Cream

3%-Diclofenac-Nano-Emulsion Cream

Intervention Type: DRUG

Placebo cream

Placebo cream

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Males and females 50 years of age and above.

2. Patients with primary osteoarthritis in at least a single knee joint, grade 2 or 3 based on the Kellgren and Lawrence classification system.

3. Radiographic evidence consistent with OA carried out within the 6 months before screening.

4. Pain should have been present for at least half of the days in the previous month and for at least 48h prior to the screening visit.

5. Eligible subjects must have used an oral, topical or rectal NSAID within the past 6 months before screening.

6. At baseline, after a 1 week withdrawal period of analgesic/anti-inflammatory medications, subjects should have a flare of pain.

7. Able to read, comprehend, and sign the consent form.

8. Examined by the authorized physician and medically cleared to participate in the study.

9. In general good health and have no contraindications to any of the investigational medicinal products.

Exclusion Criteria

1. Secondary osteoarthritis.

2. Presence of a serious or unstable medical condition (e.g., malignancy, severe neurological impairment or uncontrolled hypertension) or poor general health interfering with compliance or assessment at the study physician's discretion.

3. OA causing significant pain in any joint other than the knees.

4. Any other rheumatic or non-rheumatic joint disease or any other painful condition within the past month (e.g. fibromyalgia).

5. Knee surgery or other knee trauma at any time during the previous year or subjects for whom a treatment is planned within the study period that could alter the degree or nature of pain (e.g. arthroscopic techniques, osteotomy, joint replacement surgery etc.).

6. Active or history of gastrointestinal ulceration or bleeding within the past 5 years.

7. Presence of a significant active psychiatric disorder including major depression or subjects receiving anti-psychotic medication.

8. Existence of any dermatological condition on the knee.

9. Subjects with disabling congestive heart failure (CHF), angina, pulmonary disease.

10. Clinically significant abnormal blood results.

11. Subjects cannot have had an arthrocentesis prior or during the study.

12. Concomitant treatment with physical and/or occupational therapy.

13. Prior use of any type of NSAID or other analgesic before taking the first dose of investigational medicinal product. Rescue treatment will be allowed during the study

14. Change in sedative or CNS/psychotropic agent within the past month.

15. Chronic treatment with anticoagulants (e.g. Warfarin).

16. Subjects under treatment with corticosteroids.

17. Subjects using topical analgesics including OTC products.

18. Females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test.

19. Active alcoholism or substance abuse.

20. Has taken an investigational drug or has used an investigational device within the past 30 days.

21. History of hypersensitivity and/or idiosyncrasy to diclofenac or excipients employed in this study, aspirin or other NSAIDS.

22. Has previously been entered into this study.

23. Any condition that in the investigator's judgement precludes participation in the study.

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pharmos

INDUSTRY

Sponsor Role: lead

Responsible Party

Pharmos Ltd

Principal Investigators

Eisenberg Elon, MD

Role: PRINCIPAL_INVESTIGATOR

Rambam Health Care Campus

Locations

Barzilai Medical Center

Ashkelon, Israel, Israel

Rabin Medical Center

Petah Tikva, Israel, Israel

Rambam Medical Center

Haifa, , Israel

Sourasky Medical Center

Tel Aviv, , Israel

Countries

Israel

Other Identifiers

PH-2007-2

Identifier Type: -

Identifier Source: org_study_id